| Literature DB >> 26636483 |
Jhudit Pérez-Escuredo1, Rajesh K Dadhich1, Suveera Dhup1, Andrea Cacace1, Vincent F Van Hée1, Christophe J De Saedeleer1, Martina Sboarina1, Fabien Rodriguez1, Marie-Joséphine Fontenille1, Lucie Brisson1, Paolo E Porporato1, Pierre Sonveaux1.
Abstract
Oxygenated cancer cells have a high metabolic plasticity as they can use glucose, glutamine and lactate as main substrates to support their bioenergetic and biosynthetic activities. Metabolic optimization requires integration. While glycolysis and glutaminolysis can cooperate to support cellular proliferation, oxidative lactate metabolism opposes glycolysis in oxidative cancer cells engaged in a symbiotic relation with their hypoxic/glycolytic neighbors. However, little is known concerning the relationship between oxidative lactate metabolism and glutamine metabolism. Using SiHa and HeLa human cancer cells, this study reports that intracellular lactate signaling promotes glutamine uptake and metabolism in oxidative cancer cells. It depends on the uptake of extracellular lactate by monocarboxylate transporter 1 (MCT1). Lactate first stabilizes hypoxia-inducible factor-2α (HIF-2α), and HIF-2α then transactivates c-Myc in a pathway that mimics a response to hypoxia. Consequently, lactate-induced c-Myc activation triggers the expression of glutamine transporter ASCT2 and of glutaminase 1 (GLS1), resulting in improved glutamine uptake and catabolism. Elucidation of this metabolic dependence could be of therapeutic interest. First, inhibitors of lactate uptake targeting MCT1 are currently entering clinical trials. They have the potential to indirectly repress glutaminolysis. Second, in oxidative cancer cells, resistance to glutaminolysis inhibition could arise from compensation by oxidative lactate metabolism and increased lactate signaling.Entities:
Keywords: Cancer; Glutamine; Hypoxia-inducible factor (HIF); Tumor metabolism; c-Myc; glutaminolysis; hypoxia-inducible factor-2 (HIF-2); lactate signaling; monocarboxylate transporter 1 (MCT1)
Mesh:
Substances:
Year: 2016 PMID: 26636483 PMCID: PMC4825768 DOI: 10.1080/15384101.2015.1120930
Source DB: PubMed Journal: Cell Cycle ISSN: 1551-4005 Impact factor: 4.534